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NHLRC1Lafora disease is a form of progressive myoclonic epilepsy with autosomal recessive transmission. Two genes
have been identiﬁed so far: EPM2A and NHLRC1, and a third gene, concerning a pediatric onset subform, has
been recently proposed. We report the case of a 23-year-old woman of Turkish origin with an unusual disease
course. Clinical onset was at the age of 19 years with tonic–clonic seizures, followed by cognitive impairment;
EEG was in favor of Lafora disease, and the mutation c.436GNA (a missense mutation substituting aspartic acid
in asparagine) in the NHLRC1 gene conﬁrmed this diagnosis. After 5 years of evolution, the patient only has
moderate cognitive impairment. Some NHLRC1 mutations, particularly c.436GNA, are associated with a slower
clinical course, but there are conﬂicting data in the literature. This case strengthens the hypothesis that the
c.436GNA mutation in the NHLRC1 gene leads to less severe phenotypes and late-onset disease.
© 2013 . Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Lafora disease is a form of progressive myoclonic epilepsy with
autosomic recessive transmission. Clinical signs include myoclonus,
cognitive disorders, and generalized or occipital seizures. EEG record-
ings show slow background, anteroposterior dedifferentiation, and dif-
fuse, irregular spike–waves, together with marked occipital spikes and
photosensitivity. Pathology shows periodic acid Schiff (PAS)-positive
Lafora bodies on skin or liver biopsy, but molecular biology is nowadays
considered essential. Two genes have been identiﬁed so far, the ﬁrst one
is EPM2A [1,2] with the 6q24 mutation present in 80% of cases. This
gene codes for laforin, a dual speciﬁcity phosphatase that plays a part
in the elimination process of intracellular glycosans. The second gene
is NHLRC1 [3], also named EPM2B (with 6p22 as the most frequent
mutation) which codes for malin, an ubiquitin ligase that plays a
part in laforin destruction. A third gene (PRDM8, with the c.781TNC
(Phe261Leu) mutation) has been recently reported that codes for a
protein possibly interacting with laforin and malin and that could be
expressed in a childhood-onset subform of Lafora disease [4].
We are reporting the case of a 23-year-old woman of Turkish origin.
She had no particular medical history during childhood and adolescence.erms of the Creative Commons
rmits non-commercial use, dis-
original author and source are
lée).
evier Inc. This is an open access articHer parents were cousins. At the age of 20, she experienced for the ﬁrst
time generalized tonic–clonic seizures during herﬁfthmonth of pregnan-
cy,whichwere treatedwith lamotrigine and clobazam. Seizures persisted
with a frequency of one per month until delivery. Cerebral MRI and stan-
dard blood testswere normal. EEG recordings showed a slowbackground
with generalized spikes and spike–waves (Fig. 1). After delivery, leveti-
racetam was added because seizures were not well controlled. When
she was 21, the patient presented the ﬁrst signs of cognitive impairment.
Neuropsychological evaluation showed a frontal syndrome associated
with an anomic aphasia and memory impairment. Video-EEG made in
2010 showed theta waves and delta waves of large amplitude in anterior
regions, with a 2-Hz frequency, which decreased with eyes opening and
increased with hyperpnea, and short bursts of generalized spikes and
spike–waves. Lamotrigine was stopped, levetiracetam was decreased,
and zonisamide was introduced. One month after these modiﬁcations,
seizure frequency decreased (she had one seizure between March and
June 2010). Progressive myoclonic epilepsy was suggested. Mutation
screening was performed in the EPM2A and NHLRC1 genes as previously
reported [5]. The c.436NA substitution, leading to a change of a highly
conserved aspartic acid to asparagine in codon 146 in the NHLRC1 gene
at ahomozygote state,wasdetected. At the ageof 22, cognitive evaluation
showed progressive worsening, with alteration of memory, language,
attention, and executive functions.
The case is characterized by the late onset and slow disease progres-
sion: four years after the ﬁrst signs, the patient is still able to walk, talk,
and live at home. She never presented myoclonus. Because of this un-
usual clinical presentation, the diagnosis of Lafora disease was onlyle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1.Mrs. C.'s EEG (10 μV/mm, 0.3 s, 70 Hz, longitudinal assembly). We can observe a slow background of theta frequency with bursts of diffuse spike and polyspike–waves.
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be associatedwith a later onset of the clinical signs and a slower disease
course, as described by Gomez-Abad et al. [6] and Baykan et al. [7]. TheTable 1
Cases with the c.436GNA mutation reported in literature.
Author Age at onset Origin Myoclonus Type of seizures EEG
Lanoiselée 19 Turkish − GTCSs Slow BG
Baykan 19 Turkish + GTCSs Slow BG, genera
spike–waves an
polyspike–wave
Baykan 21 Turkish + GTCSs Slow BG, genera
spike–waves an
polyspike–wave
Baykan 17 Turkish + GTCSs Slow BG, genera
spike–waves an
polyspike–wave
Baykan 21 Turkish + GTCSs Slow BG, genera
spike–waves an
polyspike–wave
Salar 30 Turkish − GTCSs Slow BG, diffuse
spikes and wave
Couarch 13 Turkish + GTCSs, absence Slow BG, diffuse
epileptic abnorm
Couarch 13 Turkish +
Franceschetti 15 Italian + Myoclonus
Franceschetti 18 Italian GTCSs
Franceschetti 13 Italian Absence
GTCSs: generalized tonic–clonic seizures.
PS: photosensitivity.
BG: background.p.Asp146Asn/D146Nmutation found in our patient has been previously
reported in eleven subjects in the literature (Table 1) [7–10]. This muta-
tion was found in another consanguineous Lafora family who did notSex Clinical status at time of study Seizure
frequency
Age at the time
of study
W Cognitive impairment 1/month 24
lized
d
s
M Mild myoclonus, GTCSs,
moderate cognitive impairment
1 to 4/year 32
lized
d
s
M Mild myoclonus, GTCSs,
moderate cognitive impairment
1 to 4/year 29
lized
d
s
M Moderate cognitive impairment 1/year 28
lized
d
s
M Minor myoclonus, GTCSs,
slight cognitive decline
b1/year 25
s
M Dementia, extrapyramidal signs 48
and FT
alities, PS
W Severe intellectual impairment,
ataxia disabling myoclonus
27
M
M Mild cognitive and motor
impairment, preserved daily
living activities, social interaction
2
M Mild cognitive and motor
impairment, preserved daily
living activities, social interaction
28
W Mild cognitive and motor
impairment, preserved daily living
activities, social interaction
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relatives reported by Baykan et al. [7], the mean age at onset was
19.5 years old. Another patient with slow disease course and without
myoclonus was reported by Salar et al. [10]; this subject had the same
mutation as our patient. The mean age at onset in patients with the
D146Nmutation reported in the literature is 18 years old; thismutation
is the only one reported with such late ages at onset. However, there are
conﬂicting data in the literature. Other authors reported cases of patients
with the NHLRC1mutation that were different from the c.436GNAmuta-
tion and which were associated with fast evolution and severe
impairment [5,8,11].
In healthy subjects, the laforin–malin complex plays a part in the
protein targeting to glycogen (PTG) destruction process, so it acts as
a brake in glycogen production. Couarch et al. [9] reported that
NHLRC1 mutations result in glycogen accumulation. These muta-
tions affect the malin–laforin interaction and the PTG ubiquitination.
The slower disease course in patients with D146N mutations could
be explained by a partial preservation of enzymatic activity of the
D146N variant that is not observed with other mutations. Lafora
disease presents an important genetic heterogeneity, and there
may be cases with late onset and slower progression in association
with NHLRC1 mutations, which may cause a partial loss of function.
It must be noted, however, that EEG remains typical for Lafora disease
even in such atypical cases.
Lafora disease is still a mysterious affection. This case report
shows that the clinical signs of Lafora disease can be different from
the usual description made in 1911 [12]; it is conceivable that
some less severe cases remain unknown. Because of unusual presen-
tations, EEG is sometimes the only clue that hints at the possibility of
Lafora disease. The relationship between phenotype and genotype is still
incompletely understood.Conﬂict of interest
None of the authors has any conﬂict of interest to disclose.
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